How Does GIP Work? Mechanism of Action, Per the Research

Glucose-dependent insulinotropic polypeptide (GIP) is one of the two classical incretin hormones. This page summarises how published pharmacology and physiology papers describe its receptor target, its intracellular signalling and its downstream effects, and separates mechanisms that are well established from mechanisms that reviews still describe as proposed or contested. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or treatment. No doses, protocols or outcome expectations are described here.

What GIP Is and Where It Comes From

GIP was originally named gastric inhibitory polypeptide before its insulin-releasing properties led to the current name; a review of incretin biology described GIP as a peptide secreted from enteroendocrine K cells concentrated in the proximal small intestine, while the related incretin GLP-1 is secreted from L cells that are more abundant distally (PMID 17498508). The same review described both hormones as components of the incretin effect — the observation that orally ingested glucose elicits a larger insulin response than an intravenous glucose load producing matched glycaemia (PMID 17498508).

A 2023 review of incretin hormones in type 2 diabetes similarly framed GIP and GLP-1 as nutrient-stimulated hormones whose combined action accounts for a substantial share of post-meal insulin secretion in healthy physiology (PMID 37430117). Both peptides were reported to be rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminus and sharply limits the circulating half-life of the intact hormones (PMID 23684623).

How GIP Secretion Is Triggered

Secretion is the first step in the mechanism. A 2024 review of the cellular mechanisms of incretin hormone secretion described enteroendocrine cells as chemosensors that detect luminal nutrients — carbohydrate, fat and protein breakdown products — through transporters and G protein-coupled nutrient receptors, with the resulting changes in membrane potential and intracellular calcium driving vesicular release of GIP and GLP-1 (PMID 38240302). The authors of that review noted that K cells and L cells share many sensing pathways but differ in regional distribution and in their relative responsiveness to specific macronutrients (PMID 38240302).

The GIP Receptor and Its Established Signalling

The core of GIP pharmacology is the GIP receptor (GIPR). A widely cited review of incretin pharmacology and mechanisms described GIPR and the GLP-1 receptor as class B (secretin-family) G protein-coupled receptors that couple primarily to Gs, activating adenylate cyclase and raising intracellular cyclic AMP (cAMP), with downstream effectors including protein kinase A and the cAMP sensor Epac2 (PMID 23684623). In the beta cell, that review reported that this cAMP-dependent signalling amplifies the insulin secretory response that is initiated by glucose metabolism, closure of ATP-sensitive potassium channels and calcium entry — which is why the insulinotropic action is described as glucose-dependent rather than unconditional (PMID 23684623).

A 2024 review of the mechanisms of action of GLP-1 and dual GIP/GLP-1 receptor agonists described the same receptor architecture as the pharmacological basis for engineered agonists, which were designed to engage one or both incretin receptors while resisting DPP-4 degradation (PMID 39114288).

Signalling steps as described in the literature

1. Nutrient ingestion stimulates K-cell secretion of GIP, as described for enteroendocrine nutrient sensing (PMID 38240302).
2. GIP binds GIPR, a Gs-coupled class B GPCR (PMID 23684623).
3. Adenylate cyclase activation raises cAMP; PKA and Epac2 are engaged (PMID 23684623).
4. In beta cells, this amplifies glucose-stimulated insulin secretion (PMID 17498508).
5. Circulating intact GIP is cleaved by DPP-4, terminating the signal (PMID 23684623).

Pancreatic Actions: Beta Cells and Alpha Cells

Beyond acute insulin release, the incretin biology review described GIP receptor signalling in rodent and in-vitro beta-cell models as supporting beta-cell proliferation and survival pathways, while cautioning that the translation of those islet findings to humans was not established to the same degree (PMID 17498508).

A clear point of divergence between the two incretins concerns the alpha cell. A 2020 review asking how GIP may enhance the therapeutic efficacy of GLP-1 reported that GIP stimulates glucagon secretion, particularly at low or normal glucose levels, whereas GLP-1 suppresses it — so combining the two was proposed to produce a more glucose-dependent net effect on islet hormone output than either alone (PMID 32396843). A 2023 review contrasting the cardiometabolic actions of GIP and GLP-1 described the same glucagonotropic property of GIP as one of the central differences between the two hormones (PMID 36509857).

Beyond the Pancreas: Adipose Tissue, Bone and Brain

GIPR expression is not restricted to islets. The 2023 Nature Reviews Endocrinology review reported GIPR expression in adipose tissue, bone, and regions of the central nervous system, and described adipose GIPR signalling as contributing to postprandial lipid handling, including effects on triglyceride clearance and adipose tissue blood flow (PMID 36509857). The same review noted that GLP-1 and GIP diverge in several extra-pancreatic tissues, so conclusions about one incretin cannot be transferred to the other (PMID 36509857).

A 2021 pathophysiological update on GIP and GLP-1 in metabolic and cardiovascular disease similarly described extra-pancreatic GIP actions in adipose tissue and bone, and reported that the relative weight of these actions in human physiology remained incompletely resolved (PMID 34310013). A 2025 review of incretin hormones and obesity discussed central nervous system incretin receptor signalling as a route through which these hormones influence food intake and energy balance (PMID 39576749).

How GIP Signalling Differs in Type 2 Diabetes

One of the most replicated observations in this field concerns impaired GIP responsiveness. The 2023 Diabetologia review on incretin hormones and type 2 diabetes reported that the insulinotropic effect of GIP is markedly diminished in people with type 2 diabetes, while the insulinotropic effect of GLP-1 is comparatively better preserved (PMID 37430117). The incretin pharmacology review described the same loss of GIP responsiveness and discussed beta-cell GIPR expression and glucotoxicity among the mechanisms investigated to explain it (PMID 23684623). That observation is part of why GIP was, for years, considered a less attractive pharmacological target than GLP-1, as the 2020 review on combining the two incretins recounted (PMID 32396843).

GIP in Multi-Receptor Pharmacology

Much of the recent mechanistic literature concerns engineered peptides that engage GIPR alongside other receptors. A 2020 pharmacology study characterised tirzepatide as an imbalanced and biased dual GIP and GLP-1 receptor agonist: the study reported potency at the GIP receptor comparable to native GIP but weaker relative activity at the GLP-1 receptor compared with native GLP-1, together with signalling bias favouring cAMP generation over beta-arrestin recruitment and reduced GLP-1 receptor internalisation (PMID 32730231). Researchers framed those receptor-level properties as a possible explanation for pharmacology that is not simply the sum of two separate agonists (PMID 32730231).

The 2024 mechanisms review covered GLP-1 and dual GIP/GLP-1 receptor agonists together, describing their shared reliance on incretin receptor signalling and their therapeutic applications in metabolic disease (PMID 39114288). A 2022 preclinical study — animal work, not human data — reported that next-generation GLP-1/GIP/glucagon triple agonists normalised body weight in obese mice, which the authors presented as proof of concept for engaging three receptors simultaneously (PMID 35809773). Findings in rodents do not establish the same effects in humans.

The Agonism-Versus-Antagonism Question

A genuinely unresolved area, and one the literature labels as such, is whether activating or blocking GIPR is the more useful strategy for body-weight pharmacology. A 2023 review of the expanding incretin universe described this as an active controversy, noting that both GIPR agonism and GIPR antagonism have been reported to produce weight-lowering effects in preclinical and clinical settings, and that the reconciling mechanism is still debated (PMID 36976349). The 2021 pathophysiological update likewise discussed opposing interpretations of GIPR manipulation in metabolic disease (PMID 34310013), and the 2025 obesity review placed incretin receptor pharmacology within an evolving understanding of energy balance regulation (PMID 39576749). Proposed explanations in these reviews include receptor desensitisation following sustained agonism and differing contributions of central versus peripheral GIPR populations (PMID 36976349).

Established Mechanism Versus Proposed Mechanism

Tolerability and Adverse Events: What Studies Report

The papers summarised on this page were pharmacology, physiology and mechanism reviews rather than safety analyses, so they do not provide adverse-event tabulations for GIP or GIP-based agents. The 2024 review covered mechanisms of action alongside therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists (PMID 39114288), and the 2023 Diabetologia review discussed incretin-based therapy in the context of type 2 diabetes pathophysiology (PMID 37430117); neither is a substitute for regulatory product labelling or clinical trial safety reporting. Readers interested in tolerability data should consult trial publications and approved prescribing information rather than mechanism reviews.

Limitations of the Mechanistic Picture

• Several receptor-level findings come from cell-based assays; the tirzepatide characterisation, for example, was an in-vitro pharmacology study of receptor potency, bias and internalisation (PMID 32730231).
• Body-weight findings for triple agonism were generated in obese mice, not humans (PMID 35809773).
• Species differences in incretin receptor distribution and in beta-cell biology complicate translation, as discussed across incretin reviews (PMID 23684623).
• The direction of therapeutic GIPR manipulation remains contested in the current literature (PMID 36976349).

Taken together, researchers have established GIP as a nutrient-stimulated gut hormone acting through a Gs-coupled receptor to amplify glucose-dependent insulin secretion, with additional actions on alpha cells, adipose tissue, bone and brain that reviews continue to characterise (PMID 36509857, PMID 34310013). Nothing on this page describes how any compound should be used.

References

• Biology of incretins: GLP-1 and GIP (Gastroenterology, 2007)
• Pharmacology, physiology, and mechanisms of incretin hormone action (Cell Metabolism, 2013)
• How May GIP Enhance the Therapeutic Efficacy of GLP-1? (Trends in Endocrinology and Metabolism, 2020)
• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update (Diabetes, Obesity & Metabolism, 2021)
• Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (Molecular Metabolism, 2022)
• Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 (Nature Reviews Endocrinology, 2023)
• The expanding incretin universe: from basic biology to clinical translation (Diabetologia, 2023)
• Incretin hormones and type 2 diabetes (Diabetologia, 2023)
• Cellular mechanisms of incretin hormone secretion (Journal of Molecular Endocrinology, 2024)
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists (Frontiers in Endocrinology, 2024)
• Incretin hormones and obesity (The Journal of Physiology, 2025)